TLPH Share Price Performance
US$1.11
0.49 (79.76%)
65.8% undervalued intrinsic discount
US$3.25
Fair Value
Price US$1.11
AnalystConsensusTarget US$3.25
Fair ValueUS$3.25
Share Pricen/a
Talphera, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
TLPH Community Narratives
AN
Fair Value US$3.25 65.8% undervalued intrinsic discount
Regional Anticoagulant Adoption Will Drive Long Term Opportunity In Renal Replacement Therapy
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Regional Anticoagulant Adoption Will Drive Long Term Opportunity In Renal Replacement Therapy
Catalysts About Talphera Talphera is a clinical stage biopharmaceutical company developing Niyad, a regional anticoagulant designed for use in continuous renal replacement therapy. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$3.25
65.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
745.58% p.a.
Profit Margin
20.88%
Future PE
64.25x
Price in 2028
US$2.22
Trending Discussion
Recently Updated Narratives
AN
Regional Anticoagulant Adoption Will Drive Long Term Opportunity In Renal Replacement Therapy
Fair Value: US$3.25 65.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Talphera, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.27
- -20,596.43%
- -44,503.57%
- 33.9%
About TLPH
- Founded
- 2005
- Employees
- 13
- CEO
- WebsiteView website
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is based in San Mateo, California.
